Serum ferritin change rate combined with a multidimensional inflammation model for predicting efficacy and survival in extensive-stage small-cell lung cancer patients undergoing immunotherapy: a single-center, retrospective cohort study
Our study suggests that the serum ferritin change rate combined with the NLR and LDH inflammation model can serve as a biomarker for predicting the efficacy and survival outcomes of immunotherapy in ES-SCLC.
Authors
- Xin Liu (ORCID: https://orcid.org/0000-0002-7869-4730)
- M Z Li
- Yalan Liu (ORCID: https://orcid.org/0000-0002-6707-195X)
- Yudong Su
- P. Chen
- Yurong Li
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- The Central Hospital of Shaoyang (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.3389/fimmu.2026.1755851
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tianjin Medical University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences